Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals

 Since your cerebral blood flow went to hell during your stroke, what EXACTLY has your doctor done to normalize it since then and prevent this problem from happening?

Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals

Jarith L Ebenau, Denise Visser, Sander C J Verfaillie, Tessa Timmers

Eur J Nucl Med Mol Imaging. 2022 Sep 8 [Epub ahead of print]

PURPOSE The role of cerebral blood flow (CBF) in the early stages of Alzheimer's disease is complex and largely unknown. We investigated cross-sectional and longitudinal associations between CBF, amyloid burden, and cognition, in cognitively normal individuals with subjective cognitive decline (SCD). METHODS We included 187 cognitively normal individuals with SCD from the SCIENCe project (65 ± 8 years, 39% F, MMSE 29 ± 1). Each underwent a dynamic (0-70 min) [¹⁸F]florbetapir PET and T1-weighted MRI scan, enabling calculation of mean binding potential (BP_ND; specific amyloid binding) and R₁(measure of relative (r)CBF). Eighty-three individuals underwent a second [¹⁸F]florbetapir PET (2.6 ± 0.7 years). Participants annually underwent neuropsychological assessment (follow-up time 3.8 ± 3.1 years; number of observations n = 774). RESULTS A low baseline R₁was associated with steeper decline on tests addressing memory, attention, and global cognition (range betas 0.01 to 0.27, p 

Source: European Journal of Nuclear Medicine and Molecular Imaging